Core Viewpoint - The ICBC Medical Care Stock Fund (000831) has shown positive performance with a recent net value of 2.5640 yuan, reflecting a growth of 2.07% [1] Performance Summary - The fund's one-month return is 4.48%, ranking 672 out of 1022 in its category - Over the last three months, the return is 7.69%, with a ranking of 96 out of 1009 - Year-to-date, the return stands at 12.51%, ranking 128 out of 999 [1] Holdings Overview - The top ten holdings of the fund account for a total of 39.79%, with the following key positions: - Heng Rui Medicine: 8.90% - WuXi AppTec: 5.12% - Aier Eye Hospital: 4.94% - BeiGene: 3.77% - Zai Lab: 3.52% - New Horizon Health: 3.27% - Mindray Medical: 2.80% - Yuyue Medical: 2.76% - United Imaging Healthcare: 2.47% - Innovent Biologics: 2.24% [1] Fund Details - The ICBC Medical Care Stock Fund was established on November 18, 2014, and as of March 31, 2025, it has a total scale of 2.724 billion yuan - The fund is managed by Zhao Bei and Ding Yang [1][2]

Group 1 - The core viewpoint of the news is the performance and holdings of the China Europe Medical Health Mixed Fund C, which has shown a recent net value increase and varying returns over different time frames [1] - As of May 20, 2025, the fund's latest net value is 1.5473 yuan, reflecting a growth of 2.76% [1] - The fund's one-month return is 5.29%, three-month return is 0.92%, and year-to-date return is 2.57%, with respective rankings of 3149 out of 4647, 1587 out of 4590, and 3094 out of 4546 [1] Group 2 - The top ten stock holdings of the fund account for a total of 55.30%, with significant positions in companies such as Heng Rui Pharmaceutical (10.60%), WuXi AppTec (9.95%), and Kanglong Chemical (6.24%) [1] - The fund was established on September 29, 2016, and as of March 31, 2025, it has a total scale of 15.566 billion yuan [1] - The fund manager, Ge Lan, has a background in biomedical engineering and has held various positions in research and fund management since joining China Europe Fund Management in 2014 [2]

FANGDA PARTNERS http://www.fangdalaw.com 中国深圳市福田区中心四路 1 号 电子邮件 E-mail: email@fangdalaw.com 嘉里建设广场 T1 座 9 楼 电 话 Tel.: 86-755-8159-3999 邮政编码：518048 传 真 Fax: 86-755-8159-3900 9/F, Tower One, Kerry Plaza 1 Zhong Xin Si Road Futian District Shenzhen 518048, China 上海市方达（深圳）律师事务所 关于深圳迈瑞生物医疗电子股份有限公司 2024 年年度股东大会的 法律意见书 致：深圳迈瑞生物医疗电子股份有限公司 上海市方达（深圳）律师事务所（以下简称"本所"）是具有中华人民共和国 法律执业资格的律师事务所。根据相关法律顾问协议，本所指派律师出席深圳迈 瑞生物医疗电子股份有限公司（以下简称"迈瑞医疗"或"公司"）2024 年年度股东 大会（以下简称"本次股东大会"），并就本次股东大会的召集和召开程序、出席 和召集会议人员的资格、表决程序和表决结果等有关事宜出具本法律意 ...

郭艳美女士由第八届董事会非职工代表董事变更为第八届董事会职工代表 董事，任期至第八届董事会任期届满之日止。本次选举完成后，公司董事会中兼 任高级管理人员职务的董事以及由职工代表担任的董事总计不超过公司董事总 数的二分之一。 特此公告。 深圳迈瑞生物医疗电子股份有限公司董事会 2025 年 5 月 20 日 证券代码：300760 证券简称：迈瑞医疗 公告编号：2025-019 深圳迈瑞生物医疗电子股份有限公司 关于选举产生第八届董事会职工代表董事的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 根据《中华人民共和国公司法》（以下简称"《公司法》"）、《上市公司章程指 引》等法律法规及《深圳迈瑞生物医疗电子股份有限公司章程》（以下简称"《公 司章程》"）等有关规定，为保证深圳迈瑞生物医疗电子股份有限公司（以下简称 "公司"或"迈瑞医疗"）董事会的合规运作，公司于 2025 年 5 月 20 日召开了 职工代表大会，经与会职工代表审议，一致同意选举郭艳美女士（简历见附件） 担任公司第八届董事会职工代表董事。 郭艳美，女，1963 年出生，中国国籍，无境外永久 ...

证券代码：300760 证券简称：迈瑞医疗 公告编号：2025-018 一、重要提示 1. 本次股东大会未出现否决议案的情形。 2. 本次股东大会不涉及变更以往股东大会决议。 二、会议召开情况 （一）会议召开时间 （1）现场会议：2025年5月20日15:00 （2）网络投票：通过深圳证券交易所交易系统进行网络投票的具体时间为：2025年5月20 日9:15-9:25、9:30-11:30，13:00-15:00；通过深圳证券交易所互联网投票系统进行网络投票的具 体时间为：2025年5月20日9:15至15:00期间的任意时间。 深圳迈瑞生物医疗电子股份有限公司 2024年年度股东大会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导 性陈述或重大遗漏。 （二）现场会议召开地点：深圳市南山区高新技术产业园区科技南十二路迈瑞总部大厦会 议室 （三）会议召集人 深圳迈瑞生物医疗电子股份有限公司（以下简称"公司"）董事会 （四）投票方式 本次会议采取现场投票与网络投票相结合的方式召开。 本次股东大会通过深圳证券交易所交易系统和互联网投票系统向社会公众股股东提供网 络形式的投票平台 ...

Group 1 - The core viewpoint of the articles highlights that Mindray Medical's stock closed at 223.72 yuan, down 1.01%, with a rolling PE ratio of 24.36 times and a total market capitalization of 271.25 billion yuan [1] - The average PE ratio for the medical device industry is 49.51 times, with a median of 36.17 times, placing Mindray Medical at the 53rd position in the industry ranking [1] - As of March 31, 2025, Mindray Medical had 92,191 shareholders, an increase of 9,446 from the previous count, with an average holding value of 352,800 yuan and an average holding quantity of 27,600 shares [1] Group 2 - Mindray Medical's main business includes the research, manufacturing, marketing, and service of medical devices, with key products in life information and support, in vitro diagnostics, medical imaging, electrophysiology, and vascular intervention [1] - The latest quarterly report for Q1 2025 shows that the company achieved operating revenue of 8.237 billion yuan, a year-on-year decrease of 12.12%, and a net profit of 2.629 billion yuan, down 16.81%, with a gross profit margin of 62.53% [1] - The PE ratios for Mindray Medical are 24.36 (TTM) and 23.25 (static), with a price-to-book ratio of 7.03 [2]

Core Viewpoint - The domestic medical device market is experiencing rapid growth driven by new infrastructure in healthcare, but concerns about future growth rates have emerged due to local fiscal challenges [1][2]. Group 1: Company Performance and Market Dynamics - Mindray Medical held an online performance briefing on May 16, addressing investor concerns about the impact of local fiscal pressures on hospital equipment procurement [1]. - The company noted that while local fiscal constraints are currently affecting procurement, the issuance of local special bonds has been increasing since Q1 2023, which is expected to alleviate some of these pressures [1]. - Data from Zhongcheng Medical indicates a recovery in monthly bidding for various medical devices since December 2024, although the time from bidding to revenue recognition has significantly lengthened [1]. Group 2: Procurement and Financial Data - In April, the results of the Hainan Province 2024 long-term special bond project for medical equipment procurement showed that 200 ultrasound devices were bid for, with a total budget of 190 million yuan, and Mindray won 7 packages totaling 160 devices for nearly 99 million yuan [2]. - The issuance of medical special bonds, particularly for hospital renovations and equipment procurement, has seen significant growth, with a 42.18% year-on-year increase in March 2025 [2]. Group 3: Long-term Outlook - Mindray Medical remains optimistic about the domestic market, citing long-term trends such as population aging and rising income levels that will drive demand for quality medical resources [2]. - The company is expanding its market reach through internal R&D and external acquisitions, focusing on "equipment + IT + AI" digitalization, and aims to enhance its presence in high-end markets [2]. - Analysts from Huazhong Securities and Puyin International Securities predict a rebound in Mindray's domestic market growth starting in Q3 2023, supported by easing fiscal pressures and the initiation of medical equipment update projects [3].

Market Overview - The FTSE China A50 index components showed mixed performance with logistics, chemical pharmaceuticals, and home appliances leading in gains, while the coal sector faced declines [1] Sector Performance Insurance - China Pacific Insurance, China Ping An, and China Life Insurance reported market capitalizations of 980.99 billion, 361.31 billion, and 326.32 billion respectively, with trading volumes of 6.54 million, 10.71 million, and 5.58 million [3] Alcohol Industry - Kweichow Moutai, Shanxi Fenjiu, and Wuliangye had market capitalizations of 1993.60 billion, 242.98 billion, and 501.66 billion respectively, with trading volumes of 18.64 million, 10.49 million, and 5.22 million [3] Semiconductor - Northern Huachuang, Cambricon Technologies, and Haiguang Information had market capitalizations of 231.43 billion, 284.52 billion, and 325.85 billion respectively, with trading volumes of 7.93 million, 15.80 million, and 6.32 million [3] Automotive - BYD, Great Wall Motors, and Beijing-Shanghai High-speed Railway reported market capitalizations of 1192.71 billion, 199.78 billion, and 294.15 billion respectively, with trading volumes of 37.01 million, 1.61 million, and 2.02 million [3] Oil Industry - COSCO Shipping, Sinopec, and China National Petroleum had market capitalizations of 687.67 billion, 1498.94 billion, and 254.36 billion respectively, with trading volumes of 2.16 million, 2.49 million, and 14.71 million [3] Coal Industry - China Shenhua, Shaanxi Coal and Chemical Industry, and CATL reported market capitalizations of 194.68 billion, 1198.11 billion, and 777.26 billion respectively, with trading volumes of 3.11 million, 3.58 million, and 50.90 million [3] Power Industry - Dongfang Electric, Yangtze Power, and China Nuclear Power had market capitalizations of 753.62 billion, 197.66 billion, and 341.13 billion respectively, with trading volumes of 10.66 million, 7.40 million, and 21.45 million [4] Food and Beverage - CITIC Securities, Guotai Junan, and Haitian Flavoring reported market capitalizations of 387.85 billion, 311.87 billion, and 240.72 billion respectively, with trading volumes of 1.95 million, 7.07 million, and 2.48 million [4] Consumer Electronics - Industrial Fulian, Luxshare Precision, and Heng Rui Medicine had market capitalizations of 379.50 billion, 235.47 billion, and 348.74 billion respectively, with trading volumes of 3.94 million, 17.94 million, and 15.65 million [4] Home Appliances - Gree Electric, Haier Smart Home, and Muyuan Foods reported market capitalizations of 261.19 billion, 245.55 billion, and 216.54 billion respectively, with trading volumes of 11.37 million, 5.03 million, and 4.47 million [4] Medical Devices - Mindray Medical, Wanhua Chemical, and SF Holding had market capitalizations of 178.50 billion, 224.01 billion, and 272.74 billion respectively, with trading volumes of 9.22 million, 6.67 million, and 4.36 million [4] Telecommunications - China Construction, China Unicom, and China Telecom had market capitalizations of 235.94 billion, 171.33 billion, and 466.44 billion respectively, with trading volumes of 11.23 million, 2.30 million, and 8.29 million [4] Transportation Equipment - China CRRC and Guodian NARI had market capitalizations of 209.50 billion and 184.02 billion respectively, with trading volumes of 1.15 million and 2.30 million [5]

二、中国政策支持成长性企业的发展，带动全球资产加强对创业板指的关注 国家持续推动科技创新和产业升级，创业板聚焦"三创四新"（创新、创造、创意，新技术、新产业、新 业态、新模式），战略性新兴产业占比较高，受益于国家对成长行业、新型科技行业的支持。 专题：专题｜深交所2025全球投资者大会：投资中国就是投资未来 5月19日，由深交所主办的2025全球投资者大会在深圳举行。中国证监会副主席李明在会上致辞时表 示，近期，证监会将出台深化科创板、创业板改革政策措施，为企业创新成长提供更加适配、更加包容 的制度支撑。接下来还将持续引导上市公司积极通过现金分红、回购增持、并购重组等方式提升投资价 值，不断打造高质量、有活力的上市公司群体，为全球投资者提供更多优质的投资标的。 近年来，创业板指ETF规模呈现快速增长态势，从2020年初的约200亿元增长至如今的近1200亿元。对 于创业板ETF展现强大"吸金能力"的关键支撑，富国基金创业板ETF基金经理曹璐迪认为主要有以下三 大因素： 一、创业板指成分股汇聚了国内新经济领域的核心资产，所以创业板ETF是国内外投资者关注中国成长 龙头公司的重要方式 创业板指汇聚了中国新经济领域 ...

Group 1 - The core viewpoint of the news is the performance and structure of the China Europe CSI All-Share Healthcare Equipment and Services Index Fund A, which has experienced a slight decline recently [1] - As of May 19, the fund's latest net value is 1.05 yuan, marking a continuous drop for four trading days with a cumulative decline of 1.26% [1] - The fund was established in August 2024 with a total size of 0.13 billion yuan and has achieved a cumulative return of 4.82% since inception [1] Group 2 - The fund's holder structure shows that institutional investors hold 0.10 billion shares, accounting for 91.94% of the total shares, while individual investors hold 0.01 billion shares, making up 8.06% [1] - As of March 31, 2025, the top ten holdings of the fund account for a total of 41.48%, with major investments in companies such as Mindray Medical (9.10%), Aier Eye Hospital (7.77%), and United Imaging Healthcare (6.36%) [3]